A Retrospective Registry Study Evaluating the Long-Term Efficacy and Safety of Superficial Radiation Therapy Following Excision of Keloid Scars

: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. : We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. : Medical records were reviewed of subjects treated for k...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical and aesthetic dermatology Vol. 13; no. 10; pp. 12 - 16
Main Authors Berman, Brian, Nestor, Mark S, Gold, Michael H, Goldberg, David J, Weiss, Eduardo T, Raymond, Isabelle
Format Journal Article
LanguageEnglish
Published United States Matrix Medical Communications 01.10.2020
Subjects
Online AccessGet full text
ISSN1941-2789
2689-9175

Cover

Loading…
More Information
Summary:: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. : We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. : Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. : Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. : SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
DISCLOSURES:Dr. Berman is a consultant and speaker for Sensus Healthcare. Dr. Nestor is a consultant, speaker, and member of the Advisory Board for Sensus Healthcare. Drs. Gold and Goldberg are speakers for Sensus Healthcare. Dr. Raymond is a full-time employee of and owns shares in Sensus Healthcare. Dr. Weiss has no relevant conflicts to disclose.
FUNDING:This study was sponsored by Sensus Healthcare, Boca Raton, Florida.
ISSN:1941-2789
2689-9175